Acquired genomic changes, decreased TILs and HLA class I expression were identified in patients with non-small cell lung cancer progressing on immune checkpoint inhibitors

A study reports evidence of antitumour activity by combining a GDF-15 neutralising antibody with PD-1 inhibition in cancers that are refractory/relapsed to immune checkpoint inhibitors 

Certain immunotherapy combinations that are effective in selected solid tumours may not be effective in lung cancer without targetable genetic alterations.

Analysis from MARIPOSA-2 and FLAURA2 trials show a potential change of treatment paradigm in both first- and second-line settings

The TROP2-directed ADC improved PFS with reduced toxicity compared with chemotherapy in the TROPION-Lung01 trial, but results are not practice-changing  

Clinically meaningful improvements over standard care were observed in both first and second line, as reported in the MARIPOSA and MARIPOSA-2 phase III trials 

Alectinib is the first ALK inhibitor to significantly improve DFS in a phase III trial across disease stages

Results from the LIBRETTO-431 trial reinforce the use of selpercatinib as the first-line choice and are likely to widen patient access to treatment

The bispecific EGFR/MET-directed monoclonal antibody looks set to become the standard of care in this setting, but toxicity has to be managed carefully

CheckMate 77T demonstrates significantly improved event-free survival with neoadjuvant nivolumab plus chemotherapy followed by adjuvant nivolumab compared with chemotherapy and adjuvant placebo